MA11.08 IMpower010: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC

The Phase III IMpower010 (NCT02486718) study showed a statistically significant disease-free survival (DFS) benefit with adjuvant atezolizumab vs best supportive care (BSC) following platinum-based chemotherapy for patients with PD-L1 tumour cells (TC) ≥1% (by SP263) stage II-IIIA and in all patients with stage II-IIIA NSCLC (Felip et al. Lancet 2021). High tissue tumour mutational burden (TMB-H) has been associated with clinical response to some immune checkpoint inhibitors across indications. Here we present the exploratory analysis of DFS by TMB and PD-L1 expression levels in patients with resected stage II-IIIA NSCLC from the IMpower010 study.